肿瘤细胞治疗研究
FRONTIER PAPERS
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
这些发现支持抗 BCMA/GPRC5D 双特异性 CAR T 细胞在伴骨外 EMD 的复发/难治性多发性骨髓瘤（RRMM）患者中诱导了高缓解率，且安全性可控。
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-anal
GPRC5D CAR-T 在 BCMA 治疗后场景中显示出优于工程化抗体的疗效。
B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C grou
抗BCMA CAR T细胞疗法对anti-GPRC5D CAR T细胞疗法治疗失败后的RRMM有效，且安全性可接受。
The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.
这些结果支持 RD118 是重度经治 R/R MM 患者一种高效且安全的治疗选择。
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.
这些发现将cmRNA定位为一种下一代mRNA模态，用于实现强效且可控的CAR表达，从而提供一个强大的平台，以释放mRNA技术在细胞免疫治疗和精准医学中的全部潜力。
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phas
CT071 在复发/难治性多发性骨髓瘤患者中显示出令人鼓舞的安全性特征和引人注目的活性。
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.
在这项研究中，我们对10例接受GPRC5D CAR T细胞治疗后复发患者的MM样本进行了全基因组测序和全基因组亚硫酸氢盐测序。
Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-ar
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 t
这些发现共同凸显了针对侵袭性多发性骨髓瘤患者、尤其是伴髓外疾病患者的 BCMA/GPRC5D 双靶向 CAR T 细胞疗法的潜在治疗策略，并支持在更大规模的多中心临床研究中进一步探索和验证的必要性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
